SecBot SecBot
6-K ·Filed Apr 27, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001213900-26-047783
Notable filing: 6-K
Actionable Insight ▲ Bullish

While no financial figures are provided, ASCO acceptance is a material positive for clinical credibility and investor visibility. Monitor the May 21 abstract release and subsequent trial enrollment trends in IMPACT and ACAPELLA for signs of momentum. This could support future partnership or funding opportunities.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · Apr 27, 2026 · via day close
Latest settled
+223.53%
T+60 · $3.30
Vs SPY
+218.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $1.02entry
  2. T+1 · 7mo ago 0.00%α +0.49% · $1.02
  3. T+5 · 7mo ago 0.00%α −0.40% · $1.02
  4. T+20 · 6mo ago +150.98%α +146.02% · $2.56
  5. T+60 · 4mo ago +223.53%α +218.75% · $3.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced that a pooled analysis of safety and efficacy data from 58 patients across three clinical studies of its Alpha DaRT therapy for advanced pancreatic cancer has been accepted for presentation at the 2026 ASCO Annual Meeting, a premier oncology conference. This represents a significant scientific validation of its clinical program and builds momentum for its ongoing IMPACT and ACAPELLA trials in the U.S. and France.

Key Facts

  • Abstract titled 'Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer' accepted for presentation at the 2026 ASCO Annual Meeting.
  • Pooled data includes 58 patients from three prospective clinical studies conducted in Canada and Israel.
  • ASCO is the world's largest and most prestigious oncology conference; abstract acceptance is peer-reviewed and highly competitive.
  • Alpha Tau highlighted this as a major milestone, validating the maturity and strength of its pancreatic cancer clinical evidence base.
  • The company's flagship IMPACT trial in the U.S. and ACAPELLA trial in France are actively advancing.

Financial Impact

No direct financial impact disclosed; potential long-term upside from clinical validation and de-risking of development path.

revenuedilutioncashFlow

Risk Factors

  • Pooled data is preliminary and not yet peer-reviewed in full; final results may differ.
  • Alpha Tau remains pre-revenue with significant funding needs; clinical progress does not guarantee commercial success.
  • Forward-looking statements dominate the release; actual outcomes depend on trial execution and regulatory approval.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-047783
Document: ea0287690-6k_alphatau.htm0001213900-26-047783
Document: 0001213900-26-047783-index-headers.html0001213900-26-047783
Document: 0001213900-26-047783-index.html0001213900-26-047783
Document: 0001213900-26-047783.txt0001213900-26-047783

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026